Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that primary care physicians and cardiologists expect to substantially decrease their prescribing of Lipitor when generic simvastatin is available in June 2006.

The new PhysicianForum report entitled Changing Dynamics in the Dyslipidemia Market: The Intrusion of Major Generic Statins finds that 56% of primary care physicians and 53% of cardiologists say that their first-line statin following Zocor's patent expiry will be either generic simvastatin or branded Zocor, with branded Zocor likely selected based on physicians' having assumed automatic generic substitution at the retail level. Pfizer's Lipitor (atorvastatin) will bear the brunt of this change, though most switching from Lipitor will occur in low-risk patients treated with 20 mg per day or less.

The report also surveyed pharmacy directors of HMOs. According to analyst John Ensign of Decision Resources, "HMOs' responses suggest that they are prepared to take very aggressive steps to switch patients from branded statins to the newly available generics, including offering patients free samples of the generics and instituting mandatory stepped-care treatment guidelines that, in nearly all cases, begin with the use of a generic statin."

Changing Dynamics in the Dyslipidemia Market: The Intrusion of Major Generic Statins is based on a U.S. survey of 20 HMO pharmacy directors, 72 cardiologists, and 70 PCPs. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic, and scientific factors.

About PhysicianForum

PhysicianForum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Alza's Pain Patch is the Most Eagerly Awaited Emerging Therapy for Postoperative Pain

View Now